- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01482949
A Rollover Protocol for Subjects Previously Treated With AGS-003
A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006
Study Overview
Detailed Description
AGS-003-005 is a rollover, open label, Phase II clinical study testing the biologic activity and safety of AGS-003 in subjects who have experienced either partial responses or prolonged stable disease and continue to benefit from ongoing treatment with AGS-003 in protocols AGS-003-004 or AGS-003-006.
Rollover subjects from AGS-003-004 will continue with AGS-003 monotherapy booster dosing until disease progression or until a discontinuation criterion is reached.
Subjects that progress on AGS-003 monotherapy (from the AGS-003-004 protocol) may start sunitinib treatment and re-initiate AGS-003 therapy beginning with the induction phase dosing schedule.
Rollover subjects from AGS-003-006 will continue sunitinib dosing in combination with booster dosing of AGS-003 until disease progression or until a discontinuation criterion is reached.
If a subject has disease progression due to a new tumor lesion, upon consultation between the investigator, Argos representatives and the Argos medical monitor, the subject may be considered for re-manufacture of study product (from the new metastatic lesion) and dosing with this new product in combination with sunitinib beginning with the induction phase dosing schedule.
For those subjects initiating treatment with the induction phase as described above, restaging imaging occurs at screening (baseline), prior to the fifth dose in the induction phase (as applicable) and every 12 weeks during the booster phase (at the start of the sunitinib holiday, 2 weeks prior to the next AGS-003 dose).
For subjects on combination therapy, if dosing with sunitinib is stopped due to sunitinib-related issues, treatment with AGS-003 may continue.
Close-out visits will occur upon disease progression (other than circumstances discussed above which are eligible for re-induction) or upon decision to terminate the study by the sponsor.
Quarterly follow-up for survival for each subject will occur by telephone interview for 1 year following the last AGS-003 administration or study termination.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Subjects are receiving ongoing treatment with AGS-003 in protocol AGS- 003-004 or AGS-003-006.
- Measurable disease that can be monitored per RECIST throughout the course of study participation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate hematologic function, as defined by the following criteria:
- White blood cell (WBC) ≥ 4000/µL (≥ 4.0 x 103/µL)
- Absolute neutrophil count (ANC) ≥ 1500/µL (≥ 1.5 x 103/µL)
- Platelets ≥ 100,000/µL (≥ 100 x 103/µL)
- Hemoglobin (Hgb) ≥ 9.0 g/dL
Adequate renal and hepatic function, as defined by the following criteria:
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or, if serum creatinine > 1.5 x ULN, estimated glomerular filtration rate (eGFR) ≥ 30 mL/min
- Total serum bilirubin ≤ 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
Adequate coagulation function as defined by the following criteria:
- Prothrombin time (PT) ≤ 1.5 x ULN
- Activated partial thromboplastin time (PTT) < 1.5 x ULN
- Corrected calcium ≤ 11.5 mg/dL
- Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug
- Able to abstain from taking prohibited drugs, either prescription or non- prescription, during the treatment phase of the study
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
- No brain metastases detected by magnetic resonance imaging (MRI).
Exclusion Criteria:
- Any serious medical condition considered by the investigator to constitute an unwarranted high risk for investigational treatment
- History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening computed tomography (CT) scan or MRI
- Pregnancy or breastfeeding
- Active autoimmune disease or condition requiring chronic immunosuppressive therapy
NOTE: Abnormal laboratory values for autoimmunity markers in the absence of other signs/symptoms of autoimmune disease are not exclusionary.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AGS-003 in combination with sunitinib
Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals).
Subjects that will begin sunitinib therapy will be on this arm.
|
Autologous Dendritic Cell Immunotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Clinical antitumor activity of AGS-003 will be assessed as an objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST).
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit (stable disease or response)
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Clinical benefit measured as Stable Disease (SD), Partial Response (PR), and Complete Response (CR) rate to the treatment regimen.
Tumor response is verified using standard definitions of RECIST
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Immune function
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Analyses of immune function will be performed.
This will include, but not limited to, assessment of T cell and antigen presenting cell populations, including effector memory, cytotoxic lymphocytes (CTLs), and regulatory T cells.
Blood and plasma specimens for these analyses will be collected at specified time points and is optional for subjects continuing with booster treatments.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Progression Free Survival (PFS)
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Evaluate PFS from the date of registration until PFS is reached per RECIST
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Overall Survival (OS)
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Evaluate OS from date of registration until date of death.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Treatment-emergent Adverse Events
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor incidence of treatment-emergent Adverse Events.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor clinical chemistry, hematology, and urinalysis for treatment-emergent changes from baseline
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Clinical laboratory values will be monitored for changes from baseline.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Physical Examinations
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor changes from baseline in physical examinations
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Vital Signs
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor changes from baseline in vital signs
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor signs and symptoms indicating treatment-emergent autoimmunity
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Autoimmunity evaluations will be measured by clinical signs and symptoms (e.g., rash, cytopenias, and arthralgias) and by laboratory assessments.
These assessments will be monitored as long as the subject is receiving AGS-003.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor for lymph node adenopathy
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
The draining lymph nodes (axillary and inguinal) will be evaluated for changes from baseline in size, tenderness, or inflammation.
These assessments will be monitored as long as the subject is receiving AGS-003.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Injection Site Reaction
Time Frame: From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Monitor changes from baseline in injection site reactions.
|
From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Lee F Allen, M.D., Ph.D., Argos Therapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGS-003-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
Clinical Trials on AGS-003
-
Argos TherapeuticsCompletedRenal Cell CarcinomaCanada, United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Renal Cell Carcinoma | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
McGill University Health Centre/Research Institute...Université de Montréal; Argos TherapeuticsCompletedAcquired Immunodeficiency Syndrome | HIV SeropositivityCanada
-
National Institute of Allergy and Infectious Diseases...CompletedMosquito-Borne DiseaseUnited States
-
Agensys, Inc.CompletedCarcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell HistologyUnited States, Canada
-
Astellas Pharma IncAgensys, Inc.CompletedCarcinoma | Ovarian Diseases | Ovarian Neoplasms | Ovarian CancerUnited States
-
Astellas Pharma IncAgensys, Inc.TerminatedKidney Neoplasms | Carcinoma, Renal Cell | Kidney DiseasesUnited States
-
Astellas Pharma IncAgensys, Inc.CompletedRenal Cell Carcinoma | Pharmacokinetics of AGS-16M8FUnited States
-
Argos TherapeuticsCompletedInflammation | Systemic Lupus Erythematosus (SLE)United States